日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling.

建立一套全面的高级别子宫内膜癌患者来源异种移植模型:分子亚型、基因改变和治疗靶点分析

Sato Sho, Yagishita Shigehiro, Yoshida Hiroshi, Shintani Daisuke, Ogasawara Aiko, Nishikawa Tadaaki, Yasuda Masanori, Furuuchi Keiji, Uenaka Toshimitsu, Hamada Akinobu, Hasegawa Kosei

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models

法利妥珠单抗(Farletuzumab ecteribulin)和 MORAb-109 是靶向叶酸受体 α 和间皮素的抗体药物偶联物,在预后不良的妇科癌症模型中显示出活性。

Nesic, Ksenija; Rybinski, Katherine; Ratnayake, Gayanie; Ho, Gwo-Yaw; Lim, Ratana; Radke, Marc; Neagle, Chloe; Swisher, Elizabeth M; Wakefield, Matthew J; Barker, Holly E; Furuuchi, Keiji; Scott, Clare L; Vandenberg, Cassandra J

Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity.

BB-1701 是一种靶向 HER2 的含艾立布林的抗体药物偶联物 (ADC),具有强大的旁观者效应和 ICD 活性,其临床前研究

Wang Yang, Xia Bing, Cao Lixia, Yang Jianfeng, Feng Cui, Jiang Fangdun, Li Chen, Gu Lixia, Yang Yifan, Tian Jing, Cheng Xin, Furuuchi Keiji, Fulmer James, Verdi Arielle, Rybinski Katherine, Soto Allis, Albone Earl, Uenaka Toshimitsu, Gong Likun, Liu Tingting, Qin Qiuping, Wei Ziping, Zhou Yuhong

Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models

抗体药物偶联物 MORAb-202 在 TNBC PDx 模型中表现出持久的抗肿瘤疗效

Furuuchi, Keiji; Rybinski, Katherine; Fulmer, James; Moriyama, Tomoyuki; Drozdowski, Brian; Soto, Allis; Fernando, Shawn; Wilson, Kerrianne; Milinichik, Andrew; Dula, Mary Lou; Tanaka, Keigo; Cheng, Xin; Albone, Earl; Uenaka, Toshimitsu